Literature DB >> 26406350

Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.

E Sbidian1,2,3, C Hotz4, J Seneschal5, A Maruani6, F Amelot7, F Aubin8, C Paul7, M Beylot Barry9, P Humbert10, A Dupuy11, F Caux12, N Dupin13, P Modiano14, P Lepesant14, S Ingen-Housz-Oro4,15, E Mahé16, H Bachelez17, O Chosidow4,18,15, P Wolkenstein4,15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26406350     DOI： 10.1111/bjd.14199

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

Review 1.  Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.

Authors:  Christina Fotiadou; Efstratios Vakirlis; Dimitrios Ioannides
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-10-19

Review 2.  Systematic review of immunomodulatory therapies for hidradenitis suppurativa.

Authors:  Shi Yu Derek Lim; Hazel H Oon
Journal:  Biologics       Date:  2019-05-13

Review 3.  TNF-α inhibitors in the treatment of hidradenitis suppurativa.

Authors:  Kevin T Savage; Kelsey S Flood; Martina L Porter; Alexa B Kimball
Journal:  Ther Adv Chronic Dis       Date:  2019-05-27       Impact factor: 5.091

4.  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data.

Authors:  Aikaterini Kyriakou; Anastasia Trigoni; Nikiforos Galanis; Dimitrios Sotiriadis; Aikaterini Patsatsi
Journal:  Dermatol Reports       Date:  2018-10-01

5.  Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy.

Authors:  Margaret M Lowe; Haley B Naik; Sean Clancy; Mariela Pauli; Kathleen M Smith; Yingtao Bi; Robert Dunstan; Johann E Gudjonsson; Maia Paul; Hobart Harris; Esther Kim; Uk Sok Shin; Richard Ahn; Wilson Liao; Scott L Hansen; Michael D Rosenblum
Journal:  JCI Insight       Date:  2020-10-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.